ID   Mel H
AC   CVCL_B6KQ
SY   mel H
DR   cancercelllines; CVCL_B6KQ
DR   Wikidata; Q112129268
RX   CelloPub=CLPUB00680;
RX   Patent=RU2402604;
CC   Group: Patented cell line.
CC   Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 715D.
CC   HLA typing: A*03,30; B*07,13 (Patent=RU2402604).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680).
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   CelloPub=CLPUB00680;
RA   Mikhailova I.N., Baryshnikov A.Y., Morozova L.F., Burova O.S.,
RA   Shubina I.Z., Kovalevsky D.A., Voronina E.S., Treshalina H.M.,
RA   Lushnikova A.A., Tsyganova I.V., Mazurenko N.N.;
RT   "Human skin melanoma cell lines collection.";
RL   (In) Management of malignant melanoma; None X. (eds.); pp.6.1-6.6; SM Group; Dover (2016).
//
RX   Patent=RU2402604;
RA   Mikhailova I.N., Baryshnikov A.Y., Demidov L.V., Kiselev S.L.,
RA   Burova O.S., Morozova L.F.;
RT   "Cell line of human melanoma mel H, applied for obtaining antitumour
RT   vaccine.";
RL   Patent number RU2402604, 27-Oct-2010.
//